Potential malfunctions after implantation can cause disruption in therapy; some patients may need revision surgery.

The US Food and Drug Administration (FDA) has granted fast track designation to Sumitomo Pharma America’s (SMPA) DSP-5336 for ...

Study designed to support safety profile showed nizubaglustat was safe and well tolerated Results support continued ...

LONDON (Reuters) - Health campaigners have written to U.S. regulators accusing Philip Morris International of misrepresenting ...

The FDA says anyone with “Diamond Shruumz" products should destroy and discard them after multiple people developed severe ...

VYVGART (efgartigimod alfa injection) is a human IgG1 antibody fragment that binds to the neonatal Fc reeptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. It is the first ...

Researchers found that adherence and persistence in T2D patients using oral semaglutide is similar to DPP-4i, but semaglutide ...

Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the ...

At least 58 people in at least 27 states have developed severe illness after consuming Diamond Shruumz products, including ...

VYVGART (efgartigimod alfa injection) (efgartigimod IV) is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies.

Leerink Partners analyst Marc Goodman maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) on July 14 and set a price ...

(RTTNews) - Kyverna Therapeutics Inc. (KYTX) announced that its autologous, fully human CD19 chimeric antigen receptor or CAR T-cell product candidate, KYV-101, has been designated as a Regenerative ...